The Biorepository Core (BioC) complements the services provided by the Pharmacology Core and provides the laboratory-based, epidemiological, and clinical investigators with a diverse selection of human tissue specimens necessary for research. A major goal of the Core is to accelerate the transition from basic science to clinical research by providing access to well characterized human tissue. Within the established rules ofthe Human Investigative Committee and HIPAA, the Core performs several functions. These include patient consenting, tissue collection, tissue processing, banking and storage, retrieval, and transfer of fresh frozen and formalin fixed paraffin embedded human tissue obtained from the surgical suites and endoscopic units of KCI. Key services include case identification by diagnostic categories and subsequent retrieval of pathology materials (reports, blocks, slides, banked fixed and frozen materials), providing complete and accurate pathological diagnosis and interpretations.

Public Health Relevance

; BioC services enable basic science, population science, and clinical researchers to expand further into translational research. This is accomplished by the Core providing unique malignant and benign focused tissues from its tissue bank. Additionally, KCI investigators are able to use the BioC to rapidly evaluate targets and biomarkers relevant to cancer cure. Tissues acquired through this Core come from a diverse population, aiding research into health disparities.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA022453-31
Application #
8411085
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2012-12-01
Budget End
2013-11-30
Support Year
31
Fiscal Year
2013
Total Cost
$46,094
Indirect Cost
$15,769
Name
Wayne State University
Department
Type
DUNS #
001962224
City
Detroit
State
MI
Country
United States
Zip Code
48202
Shah, Seema; Brock, Ethan J; Jackson, Ryan M et al. (2018) Downregulation of Rap1Gap: A Switch from DCIS to Invasive Breast Carcinoma via ERK/MAPK Activation. Neoplasia 20:951-963
An, Mingrui; Wu, Jing; Zhu, Jianhui et al. (2018) Comparison of an Optimized Ultracentrifugation Method versus Size-Exclusion Chromatography for Isolation of Exosomes from Human Serum. J Proteome Res 17:3599-3605
Yu, Chunsong; An, Myunggi; Jones, Evan et al. (2018) Targeting Suppressive Oligonucleotide to Lymph Nodes Inhibits Toll-like Receptor-9-Mediated Activation of Adaptive Immunity. Pharm Res 35:56
Kariburyo, Furaha; Wang, Yuexi; Cheng, I-Ning Elaine et al. (2018) Observation versus treatment among men with favorable risk prostate cancer in a community-based integrated health care system: a retrospective cohort study. BMC Urol 18:55
Thakur, Manish K; Heilbrun, Lance; Dobson, Kimberlee et al. (2018) Phase I Trial of the Combination of Docetaxel, Prednisone, and Pasireotide in Metastatic Castrate-Resistant Prostate Cancer. Clin Genitourin Cancer 16:e695-e703
Feldmann, Daniel P; Cheng, Yilong; Kandil, Rima et al. (2018) In vitro and in vivo delivery of siRNA via VIPER polymer system to lung cells. J Control Release 276:50-58
Vaishampayan, Ulka (2018) Advantages and Adversities of the Weighted Toxicity Score. Clin Cancer Res 24:4918-4920
Wang, Zhaoxian; Sau, Samaresh; Alsaab, Hashem O et al. (2018) CD44 directed nanomicellar payload delivery platform for selective anticancer effect and tumor specific imaging of triple negative breast cancer. Nanomedicine 14:1441-1454
Ravindra, Manasa; Wilson, Mike R; Tong, Nian et al. (2018) Fluorine-Substituted Pyrrolo[2,3- d]Pyrimidine Analogues with Tumor Targeting via Cellular Uptake by Folate Receptor ? and the Proton-Coupled Folate Transporter and Inhibition of de Novo Purine Nucleotide Biosynthesis. J Med Chem 61:4228-4248
Kim, Seongho; Wong, Weng Kee (2018) Extended two-stage adaptive designs with three target responses for phase II clinical trials. Stat Methods Med Res 27:3628-3642

Showing the most recent 10 out of 826 publications